drugset / Trial / NCT03838250

Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC

NCT03838250

Phase 1 Unknown 10 enrolled Pharmicell Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

This study is to evaluate the safety and efficacy of a single dose of Cellgram™ delivered via hepatic artery in patients with decompensated alcoholic liver cirrhosis.

Timeline

Start
2019-06-20
Primary completion
2021-03
Completion
2021-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous bone marrow-derived mesenchymal stem cells Cell therapy 5e+07 cells Other